Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
1127 5 |
Ultima descărcare din IBN: 2024-04-07 12:59 |
SM ISO690:2012 ILICIUC, Ion, RAILEAN, Gheorghe, GUSICOVA, Alexandra, RAILEAN, Anastasia, GUŢU, Arcadie, MAMMADOVA, Ulviyya. Aspectul terapeutic al Ronocitului (CDP-cholina) la copiii cu cefalee migrenoasă. In: Curierul Medical, 2012, nr. 6(330), pp. 42-46. ISSN 1875-0666. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Curierul Medical | ||||||
Numărul 6(330) / 2012 / ISSN 1875-0666 | ||||||
|
||||||
Pag. 42-46 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
We performed a study of the frequency and duration of migraine headaches and specific changes in EEG and dynamics of laboratory changes in serum of cardiolipin, phospholtidilcolin, sphyngomyelin and α-fetoprotein with the immunoferment screening analysis method (ELISA) before and after treatment. Ronocit was administrated parenterally and orally for a period of 40 days at a dose of 1000 mg in two divided doses. While reducing the frequency and duration of headaches in children, an increased lipid metabolism was observed, especially of phospholipids. A parenteral treatment
period of 10 days in patients with migraine headaches were compared with the results from the treatment of children with Cerebral Palsy. By analyzing side effects, of Ronocit in children with migraine headaches and cerebral palsy, we can conclude that no side effects were noted. There was a clinical and
neurophysiological (EEG) improvement in the frequency and duration of migraine access, while increasing antioxidant defense system. This aspect can be used for prophylactic migraine access in children. |
||||||
Cuvinte-cheie Ronocit, immunoferment screening., migraine, headache, Access |
||||||
|
Dublin Core Export
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'> <dc:creator>Iliciuc, I.T.</dc:creator> <dc:creator>Railean, G.P.</dc:creator> <dc:creator>Gusicova, A.</dc:creator> <dc:creator>Railean, A.</dc:creator> <dc:creator>Guţu, A.</dc:creator> <dc:creator>Mammadova, U.</dc:creator> <dc:date>2012-01-02</dc:date> <dc:description xml:lang='en'>We performed a study of the frequency and duration of migraine headaches and specific changes in EEG and dynamics of laboratory changes in serum of cardiolipin, phospholtidilcolin, sphyngomyelin and α-fetoprotein with the immunoferment screening analysis method (ELISA) before and after treatment. Ronocit was administrated parenterally and orally for a period of 40 days at a dose of 1000 mg in two divided doses. While reducing the frequency and duration of headaches in children, an increased lipid metabolism was observed, especially of phospholipids. A parenteral treatment period of 10 days in patients with migraine headaches were compared with the results from the treatment of children with Cerebral Palsy. By analyzing side effects, of Ronocit in children with migraine headaches and cerebral palsy, we can conclude that no side effects were noted. There was a clinical and neurophysiological (EEG) improvement in the frequency and duration of migraine access, while increasing antioxidant defense system. This aspect can be used for prophylactic migraine access in children. </dc:description> <dc:description xml:lang='ru'>Изучали клинические проявления, данные ЭЭГ и липидный обмен в крови (кардиолипина, фосфатидилколина, сфингомиелина) и a-фетопротеина у 42 детей (17 мальчиков и 25 девочек, средний возраст 10,8 ± 1,8 лет) с мигренозной головной болью в динамике на протяжении 9 месяцев после назначения Роноцита (в/в и перорально) в дозе 1000 мг в двух приемах, в течение 40 дней. До лечения и каждые 3 месяца после лечения, иммуноферментативным методом (ЕЛИСА) исследовали уровень фосфолипидов в крови (кардиолипина, фосфотидилколина, сфингомиелина) и a-фетопротеина. Выявили высокую активность Роноцита у всех детей нa снижение частоты и степени выраженности болевого синдрома, в то время когда обмен фосфолипидов (кардиолипина, фосфотидилколина, сфингомиелина) и a-фетопротеина повысились, независимо от возраста больного, и эта закономерность, по назначенной схеме, сохраняется на протяжении около 6 месяцев, особенно четко замечено повышение фосфолипидов. Эта закономерность выявляется более заметно у детей с мигренозной головной болью и в меньшей степени у детей с детским параличом. На фоне лечения Роноцитом побочных эффектов не выявлено. Это позволяет назначать Роноцит и с профилактической целью мигренозных приступов головных болей.</dc:description> <dc:source>Curierul Medical 330 (6) 42-46</dc:source> <dc:subject>Ronocit</dc:subject> <dc:subject>migraine</dc:subject> <dc:subject>headache</dc:subject> <dc:subject>Access</dc:subject> <dc:subject>immunoferment screening.</dc:subject> <dc:title>Aspectul terapeutic al Ronocitului (CDP-cholina) la copiii cu cefalee migrenoasă</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> </oai_dc:dc>